Novo Nordisk partners with Emcure to boost semaglutide availability
Novo Nordisk, the Danish pharma giant, is teaming up with India's Emcure Pharmaceuticals to make its blockbuster weight-loss injection, semaglutide (sold as Poviztra), more widely available across India.
Emcure will handle marketing and distribution, focusing on people dealing with obesity and related-cardiovascular risks.
Novo Nordisk's India strategy
Emcure's huge network—spanning 70+ countries—means Poviztra could reach millions who need it most.
With over 600 million Indians affected by obesity, this partnership is a big move.
Plus, semaglutide has shown strong results in clinical trials for both weight loss and lowering heart risks.
This deal also highlights how global pharma companies are increasingly partnering with Indian firms to navigate local markets and regulations.